非霍奇金淋巴瘤和霍奇金淋巴瘤幸存者在生存的头三年内对癌症复发的恐惧：法国患者的研究。
Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients.
机构信息
a Faculty of Literature and Human Sciences , Catholic Institute of Toulouse , Toulouse , France.
b Service of Medical and Clinical Pharmacology, Center of Pharmacovigilance, Pharmaco-epidemiology and Information on Drugs , Toulouse University Hospital , Toulouse , France.
出版信息
Psychol Health Med. 2019 Aug;24(7):781-787. doi: 10.1080/13548506.2019.1574354. Epub 2019 Feb 4.
The aim of this study was to measure the prevalence of FCR among a sample of French lymphoma survivors and to determine factors associated with clinical levels of FCR. The study was conducted with two cross-sectional measures: sociodemographic and anxiety, depression as well as health-related quality of life (HRQoL) scores were measured at the baseline of the post-cancer period and FCR was evaluated during the first 3 years of survivorship. The prevalence of clinical levels of FCR (≥13) was evaluated by the Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF) among non- and Hodgkin lymphoma survivors undergoing prior first-line chemotherapy. Among 108 lymphoma survivors with an average follow-up of 1.6 years (range 0.3-3.0 years), clinical levels of FCR (≥13) were observed for 44.4% (n = 48). Multivariate analysis indicated that baseline anxiety and low quality of life were related to clinically significant FCR levels.
本研究旨在测量法国淋巴瘤幸存者中 FCR 的患病率，并确定与 FCR 临床水平相关的因素。该研究采用了两种横断面测量方法：在癌症后时期的基线测量社会人口统计学和焦虑、抑郁以及健康相关生活质量（HRQoL）评分，在幸存者生存的前 3 年内评估 FCR。通过对先前接受一线化疗的非霍奇金淋巴瘤幸存者进行 Fear of Cancer Recurrence Inventory - Short Form（FCRI-SF）评估，评估 FCR 临床水平（≥13）的患病率。在 108 名平均随访 1.6 年（范围 0.3-3.0 年）的淋巴瘤幸存者中，观察到 44.4%（n=48）的 FCR 临床水平（≥13）。多变量分析表明，基线焦虑和低生活质量与临床显著的 FCR 水平相关。
Zotero 插件